The AI-enabled system helps providers to generate insights for improving patient journeys and to efficiently move patients through the system. Description The company’s technology helps hospitals and clinics manage patient…
An end-to-end platform that uses AI to discover at-risk patients and recommend treatment options. Description Using the platform, providers and healthcare organizations can receive personalized data about patients’ needs while…
Drug Name: Truqap Active Ingredient: capivasertib Indication: An AKT inhibitor used in combination with fulvestrant for the treatment of advanced HR-positive breast cancer Approval Date: 11/16/2023 Company: AstraZeneca More: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-capivasertib-fulvestrant-breast-cancer
Subtle Medical applies AI to enhance images for radiology departments. Description SubtlePET and SubtleMR work with the machines a facility already uses to speed up MRI and PET scans while…
Drug Name: Defencath Active Ingredient: taurolidine, heparin Indication: To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter (Catheter…
Drug Name: Augtyro Active Ingredient: repotrectinib Indication: To treat ROS1-positive non-small cell lung cancer Approval Date: 11/15/2023 Company: Bristol-Myers Squibb Company More: https://accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf
Drug Name: Fruzaqla Active Ingredient: fruquintinib Indication: To treat refractory, metastatic colorectal cancer Approval Date: 11/8/2023 Company: Takeda Pharmaceuticals America, IncMore: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf
Drug Name: Loqtorzi Active Ingredient: toripalimab-tpzi Indication: To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies Approval Date: 10/27/2023 Company: Coherus BioSciences, Inc More:…
Drug Name: Omvoh Active Ingredient: mirikizumab-mrkz Indication: To treat ulcerative colitis Approval Date: 10/26/2023 Company: Eli Lilly and Company More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761279s000lbl.pdf
Drug Name: Agamree Active Ingredient: vamorolone Indication: To treat Duchenne muscular dystrophy Approval Date: 10/26/2023 Company: Santhera Pharmaceuticals (USA), Inc More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215239s000lbl.pdf